|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
11 p, 421.8 KB |
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ;
John, Thomas (Department of Medical Oncology. Austin Health) ;
Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ;
Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ;
Kim, Sang-We (Department of Oncology. Asan Medical Center) ;
Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ;
Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ;
Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ;
Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ;
Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ;
Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ;
Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ;
Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ;
Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ;
Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ;
Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ;
Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296
|
|
|
3.
|
|
9 p, 1.3 MB |
A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
/
Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences) ;
Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
John, T. (Department of Medical Oncology. Austin Health) ;
Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, J.W. (David Geffen School of Medicine. University of California) ;
Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences) ;
Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine) ;
Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, H.V. (Department of Thoracic Surgery. Choray Hospital) ;
Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center) ;
Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto) ;
Zeng, L. (Late Oncology Statistics. AstraZeneca) ;
Hodge, R. (Late Oncology Statistics. AstraZeneca) ;
Atasoy, A. (Late Oncology Research and Development. AstraZeneca) ;
Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca) ;
Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. [...]
2021 - 10.2217/fon-2021-0752
Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835
|
|
|
4.
|
|
10 p, 367.0 KB |
ESMO Management and treatment adapted recommendations in the COVID-19 era : Lung cancer
/
Passaro, Antonio (IRCCS European Institute of Oncology (Milà, Itàlia)) ;
Addeo, Alfredo (Geneva University Hospitals (Suïssa)) ;
Von Garnier, Christophe (Centre Hospitalier Universitaire Vaudois) ;
Blackhall, Fiona (University of Manchester) ;
Planchard, David (Gustave Roussy) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Dziadziuszko, Rafal (Gdanski Uniwersytet Medyczny) ;
De Marinis, Filippo (IRCCS European Institute of Oncology (Milà, Itàlia)) ;
Reck, Martin (LungenClinic) ;
Bouchaab, Hasna (Centre Hospitalier Universitaire Vaudois) ;
Peters, Solange (Centre Hospitalier Universitaire Vaudois) ;
Universitat Autònoma de Barcelona
The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. [...]
2020 - 10.1136/esmoopen-2020-000820
ESMO open, Vol. 5 (january 2020)
|
|
|
5.
|
|
12 p, 942.4 KB |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
/
Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ;
Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ;
Pilotto, Sara (University of Verona (Itàlia)) ;
Drozdowskyj, Ana (Pivotal (Madrid)) ;
Codony Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ;
Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ;
Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ;
Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ;
Gervais, Radj (Centre François Baclesse (Caen, França)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ;
Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ;
Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ;
Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ;
De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ;
López-Vivanco, Guillermo (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ;
Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ;
Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ;
Bria, Emilio (University of Verona (Itàlia)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
